International Journal of Hematology

, Volume 91, Issue 5, pp 903–906

Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma

  • Hiroyuki Takamatsu
  • Takeshi Yamashita
  • Takeharu Kotani
  • Aiko Sawazaki
  • Hirokazu Okumura
  • Shinji Nakao
Case Report

DOI: 10.1007/s12185-010-0586-9

Cite this article as:
Takamatsu, H., Yamashita, T., Kotani, T. et al. Int J Hematol (2010) 91: 903. doi:10.1007/s12185-010-0586-9

Abstract

A 79-year-old female patient with multiple myeloma who had no prior cardiac disease history developed an acute myocardial infarction on day 5 after receiving bortezomib and dexamethasone (BD). After treatment of coronary stenoses by stents, she received another course of BD therapy and developed angina pectoris on day 5 after the therapy. Bortezomib’s antitumor effect is due to the inhibition of proteasome activity. This inhibition may increase endothelial progenitor cell apoptosis and decrease endothelial nitric oxide synthase/nitric oxide (eNOS/NO), thus leading to coronary spasm. It is, therefore, important to carefully monitor patients being treated with bortezomib for the potential occurrence of ischemic heart disease.

Keywords

Multiple myeloma Ischemic heart disease Bortezomib 

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Hiroyuki Takamatsu
    • 1
    • 2
  • Takeshi Yamashita
    • 1
  • Takeharu Kotani
    • 1
  • Aiko Sawazaki
    • 1
  • Hirokazu Okumura
    • 2
  • Shinji Nakao
    • 2
  1. 1.Department of Internal MedicineNTT WEST Kanazawa HospitalKanazawaJapan
  2. 2.Cellular Transplantation BiologyKanazawa University Graduate School of Medical ScienceKanazawaJapan